Samsara BioCapital is a new breed of biotech investment fund focused on translating cutting-edge biology into new therapies to treat patients with unmet medical needs. Founded in 2016 by Srinivas Akkaraju, MD, PhD, our team of scientists, investors, and entrepreneurs takes a long-term view to value creation across all stages of public and private life science companies. We believe in a collaborative, hands-on approach, working closely with entrepreneurs to harness exciting scientific advances and build leading companies. Samsara actively manages approximately US$410 million in assets on behalf of endowments, foundations, and family offices. For more information, visit www.samsaracap.com.
Charles River is a highly respected, global provider of drug discovery and non-clinical development solutions, accelerating innovative research and development of drugs to support patients in need. With a focus on clinical efficacy, we drive programs through a combination of multidisciplinary drug discovery expertise and capabilities in targets, translational platforms, therapeutic areas and across modalities. Our client-focused, collaborative approach creates true partnerships that anticipate challenges, overcome obstacles, and move us forward together on the journey of getting new drugs to market. To learn more about our unique portfolio and breadth of services, visit www.criver.com.
